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Background: The gene expressions of netrin-1 dependence receptors, DCC and UNC5C, are frequently downregulated
in many cancers. We hypothesized that downregulation of DCC and UNC5C has an important growth regulatory
function in gastric tumorigenesis.
Results: In the present study, a series of genetic and epigenetic analyses for DCC and UNC5C were performed in a
Japanese cohort of 98 sporadic gastric cancers and corresponding normal gastric mucosa specimens. Loss of
heterozygosity (LOH) analyses and microsatellite instability (MSI) analysis was applied to determine chromosomal
instability (CIN) and MSI phenotypes, respectively. More than 5 % methylation in the DCC and UNC5C promoters
were found in 45 % (44/98) and 32 % (31/98) gastric cancers, respectively, and in 9 % (9/105) and 5 % (5/105)
normal gastric mucosa, respectively. Overall, 70 % (58 of 83 informative cases) and 51 % (40 of 79 informative
cases) of gastric cancers harbored either LOH or aberrant methylation in the DCC and UNC5C genes, respectively.
In total, 77 % (51 of 66 informative cases) of gastric cancers showed cumulative defects in these two dependence
receptors and were significantly associated with chromosomal instability. Both DCC and UNC5C were inactivated
in 97 % of CIN-positive gastric cancers and in 55 % of CIN-negative gastric cancers.
Conclusions: Defect in netrin receptors is a common feature in gastric cancers. DCC alterations are apparent in
the early stages, and UNC5C alterations escalate with the progression of the disease, suggesting that the cumulative
alterations of netrin-1 receptors was a late event in gastric cancer progression and emphasizing the importance of this
growth regulatory pathway in gastric carcinogenesis.
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Global estimates of cancer incidence rank gastric cancer
as the fourth most common malignancy and the second
most common cause of cancer-related deaths worldwide
[1]. Gastric cancer is a heterogeneous disease with
multiple environmental etiologies and with alternative
pathways of carcinogenesis [2, 3]. One of the major
etiological risk factors for gastric cancer is Helicobacter
pylori (H. pylori) infection. Previous reports indicated a* Correspondence: takeshin@cc.okayama-u.ac.jp
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gastric cancer, while only 1.2–2.8 % of individuals
infected with H. pylori develop gastric cancer [4–7].
Current knowledge on the molecular mechanisms
underlying gastric carcinogenesis indicates one major
epigenetic instability pathway and two major genetic
instability pathways [8]. The major epigenetic instability
pathway is defined as the CpG island methylator pheno-
type (CIMP), which was initially described in colorectal
cancer and also observed in a subset of gastric cancers
and which harbors a critical degree of aberrant promoter
hypermethylation associated with transcriptional silen-
cing of multiple tumor suppressor genes [9, 10]. Thecle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
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lite instability (MSI) and chromosomal instability (CIN)
[8]. MSI is defined as the presence of replication errors in
simple repetitive microsatellite sequences caused by
mismatch repair (MMR) deficiencies. One is Lynch syn-
drome caused by germline mutations in MMR genes and
another is sporadic MSI caused mainly by promoter
hypermethylation in the MLH1 gene [10, 11]. On the
other hand, CIN, which is characterized by chromosomal
alterations—either qualitative or quantitative—is a more
common pathway that may comprise clinicopathologically
and molecularly heterogeneous tumors [8].
The Cancer Genome Atlas Research Network re-
cently divided gastric cancers into four subtypes [12].
Tumors were first categorized by Epstein–Barr virus
(EBV)-positivity (9 %), then by MSI-high status, here-
after called MSI-positive (22 %), and the remaining
tumors were classified by degree of aneuploidy into
those termed genomically stable (20 %) or those exhibiting
CIN (50 %). EBV-positive cancers as well as MSI-positive
cancers were known to cluster each on its own, exhibiting
extreme CIMP. Differences between the EBV-CIMP and
MSI-associated gastric-CIMP methylation profiles are ex-
emplified by the fact that all EBV-positive tumors assayed
displayed CDKN2A (p16INK4A) promoter hypermethyla-
tion but lacked the MLH1 hypermethylation characteristic
of MSI-associated CIMP.
With respect to CIN characterized by copy number
changes in chromosomes, Deng et al. used high resolution
genomic analysis to profile somatic copy number alter-
ations in a panel of 233 gastric cancers (primary tumors
and cell lines) and 98 matched gastric non-malignant
tissues. Regarding broad chromosomal regions, the most
frequently amplified region included chromosomes 1q, 5p,
6p, 7p, 7q, 8q, 13q, 19p, 20p, and 20q, and the most
frequently deleted regions included chromosomes 3p, 4p,
4q, 5q, 6q, 9p, 14q, 18q, and 21q [13].
Frequently deleted chromosomal regions are usually
characterized by loss of heterozygosity (LOH) and sug-
gest the presence of tumor suppressor genes [14, 15].
LOH on chromosome 18q21 is found in 30–71 % of
gastric cancers [13, 16–18], and DPC4 (Smad4)/DCC
have been postulated to be the major targets. DPC4
(Smad4), a tumor suppressor gene, exhibits frequent
mutations accompanied by LOH in approximately 20 %
of pancreatic cancers [19], but no mutations have been
reported in gastric cancers [20]. In contrast, few studies
have focused on DCC gene alterations, and its genetic/
epigenetic status still remains virtually unexplored in
gastric cancer, partly because of the length and complexity
of this gene [21]. Interestingly, recent studies have demon-
strated that DCC as well as UNC5C serve as dependence
receptors for netrin-1, thus, reinforcing their potential role
as tumor-suppressors in human cancers [22–25].DCC receptors are distributed along the length of the
epithelium in the intestine, whereas netrin-1 is differen-
tially expressed, forming a gradient within the gastro-
intestinal tract [24]. A high concentration of netrin-1 is
present at the crypt base where stem cells and transient
amplifying cells reside. By contrast, a low concentration
of netrin-1 exists at the tip of the villi, where many cells
are undergoing apoptosis and sloughing-off. This netrin-1
gradient was examined further using transgenic mice to
determine if netrin-1 is responsible for regulating DCC-
induced apoptosis in the intestinal epithelium [24]. The
study by Mazelin et al. indicated that netrin-1 overexpres-
sion caused a decrease in intestinal epithelial cell death,
whereas no increase in proliferation and differentiation of
cells was observed. By contrast, netrin-1–mutant new-
born mice exhibited increased cell death. Taken to-
gether, these data support the concept that netrin-1
regulates apoptosis through the DCC-dependence recep-
tor in the intestine. However, netrin-1 is unlikely to be a
direct regulator of intestinal homeostasis, given that
normal epithelial organization is not disrupted by netrin-1
overexpression [24].
Similar to DCC receptors, other netrin-1 receptors,
including UNC5A, UNC5B, and UNC5C, were also dis-
covered as putative tumor suppressor genes in various
tumors, including gastric cancer [26, 27]. In particular, a
twofold downregulation of UNC5C expression compared
with the corresponding normal tissues was observed in
approximately 70 % of gastric cancer cases [26]. This
region is located at 4q21–23, which is often a site of dele-
tion in gastric cancer and is associated with epigenetic
gene inactivation, such as promoter methylation [26–28].
In this study, we hypothesized that downregulation of
DCC and UNC5C plays an important growth regulatory
function in gastric tumorigenesis, which we addressed
by investigating a panel of gastric cancer cell lines and
clinical specimens from patients with gastric cancer.
Herein, we report that the majority of gastric cancers
show loss of both netrin-1 receptors. We also provide
data suggesting that the inactivation of these receptors is
mediated through both genetic and epigenetic mecha-
nisms. Cumulative defects in these two dependence
receptors are significantly associated with the CIN
phenotype, emphasizing the importance of these novel
findings and this growth regulatory pathway in gastric
carcinogenesis.
Results
Characteristics of gastric cancer patients
Of 98 gastric cancer patients, 34 patients were female
(35 %), and 48 tumors were pathologically diagnosed as
differentiated (49 %) (Table 1). With regard to TNM
stage, 18, 29, 37, and 14 gastric cancer patients were
classified as stage I, II, III, and IV, respectively. By tumor
Table 1 Characteristics of gastric cancer patients
Characteristic Percentage (No.)
Age Mean age (SD) 65.1 (11.8)
Gender Female 35 (34)
Male 65 (64)
Histology Diff 49 (48)
Undiff 51 (50)












Distant metastasis Negative 86 (84)
Positive 14 (14)
MSI MSI 13 (13)
Non-MSI 87 (85)
LOH Ratio Mean Ratio (SD) 0.24 (0.3)
CIN Positive 51 (50)
Negative 47 (46)
Not informative 2 (2)
KRAS Mutant 5 (5)
Wild 95 (93)
BRAF Mutant 0 (0)
Wild 100 (98)
PIK3CA Mutant 4 (3)
Wild 96 (94)
H.pyroli Positive 71 (70)
Negative 29 (28)
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displaying microsatellite instability (MSI; 13 %). The
mean LOH ratio of the 98 tumors was 0.24 (standard
deviation (SD), ±0.3).
CIN phenotype was categorized by calculating the
LOH ratio of the informative markers of the seven poly-
morphic microsatellite sequences, independently from
the 4q and 18q loci. When a tumor showed a LOH ratio
higher than 0, the tumor was categorized as CIN-
positive. By this criterion, 50/98 tumors (51 %) were
classified as CIN-positive.Direct sequencing of gastric cancer specimens revealed
the proportion of KRAS, BRAF, and PIK3CA mutations
(Table 1). Mutations were detected in the KRAS codon
12 (5 %, N = 5/98) and codon 13 (1 %, N = 1/98); BRAF
codon 600 (0 %, N = 0/98); PIK3CA codon 545 (1 %,
N = 1/98); and codon 1047 (3 %, N = 3/98). KRAS
codon 12 mutations consisted of G12D (35G to A,
N = 4) and G12R (34G to C, N = 1), and codon 13
mutations included G13D (38G to A, N = 1). Interest-
ingly, one tumor displayed both KRAS codon 12 and
13 mutations (Additional file 1: Figure S1A). PIK3CA
exon 9 mutations comprised E545K (1633G to A, N = 1),
while exon 20 mutations comprised H1047R (3140A
to G, N = 3). Furthermore, we determined the infec-
tion status of H. pylori by recovering the cagA geno-
type (Additional file 1: Figure S1B). Through this
analysis, we could recover the cagA sequence from 70
gastric cancer tissues (71 %).Methylation status of DCC in gastric cancer specimens
and association with clinicopathological features
We investigated DCC methylation status in 98 gastric
cancers and 105 normal gastric mucosa specimens.
Location of the DCC gene and the results of a panel
of representative combined bisulfite restriction ana-
lyses (COBRA) are depicted in Fig. 1a–b; these results
were analyzed as continuous variables (Fig. 1c). We
found that 56/98 gastric cancers (57 %) and 31/105
normal gastric mucosa specimens (29.5 %) displayed
more than 1.0 % methylation in the DCC promoter.
The mean methylation level was 18.3 % [95 % confi-
dence interval (CI), 14.5–22.2 %] among gastric can-
cer tissues that displayed over 1.0 % methylation in
the DCC promoter and 4.9 % (95 % CI, 3.3–6.5 %) in
the corresponding normal gastric mucosa specimens
that displayed over 1.0 % methylation (P < 0.0001,
Wilcoxon/Kruskal–Wallis test; Fig. 1c–d). Therefore,
we defined a DCC methylation of 5 % or more as a
continuous variable (i.e., >5.0 % methylation was defined
as methylation-positive (methylated) and <5.0 % methyla-
tion as methylation-negative (unmethylated)). Using this
criterion, we observed DCC methylated cases in 44/
98 gastric cancers (45 %) and in 9/105 normal gastric
mucosa (9 %).
Next, we investigated the association between DCC
promoter methylation and various clinicopathological
and genetic features. DCC methylation status was signifi-
cantly associated with MSI status. MSI-positive gastric
cancers were significantly more frequently associated with
DCC methylation than with DCC unmethylation (23 vs.
6 %, P = 0.013; Table 2). There were no significant as-
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Fig. 1 (See legend on next page.)
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Fig. 1 DCC promoter methylation and 18q LOH analyses. (a) Schematic representation of the location of the three LOH probes and DCC gene
promoter regions in chromosome 18. The red line denotes the DCC gene. Gray and black squares represent the untranslated and the coding exon
1 regions, respectively; arrows on the squares indicate transcriptional starting sites; vertical lines indicate CpG sites; white diamonds represent the
restriction sites for HhaI; thick horizontal lines depict the locations of COBRA products; arrows on the thick horizontal lines denote COBRA primers.
(b) Representative results of COBRA of DCC. Arrows indicate methylated alleles; M denotes methylation; U denotes unmethylation; Mc denotes the
methylated control; SM denotes the size marker. (c) Results of DCC methylation as a continuous variable. In the box plot diagrams, the horizontal
line within each box represents the median, the limits of each box represent the interquartile ranges, and the whiskers are the maximum and
minimum values. Each green bar represents the mean. NM denotes normal mucosa. T denotes tumor. (d) The frequency of methylation-positivity
of cancer and normal tissues according to different thresholds. (e) DCC mRNA expression levels and methylation status in 10 gastric cancer cell lines
and a human lung fibroblast cell line. DCC mRNA expression is observed (lower ΔCT) in GCIY and NHLH cell lines. DW denotes distilled water
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gastric cancer
Among informative cases, the frequencies of 18q LOH
at each microsatellite marker were 14/41 (24 %) at
D18S35, 17/55 (31 %) at D18S69, and 21/58 (36 %) at
D18S58 (the location of each maker is shown in Fig. 1a).
Tumors showing LOH at all three, two, and only one of
the three microsatellite markers were 4 (4.8 %), 9 (11 %),
and 23 (28 %) of 83 informative cases among 98 primary
gastric cancers, respectively. Tumors showing LOH in at
least one of the three microsatellite markers for 18q
LOH were categorized as 18q LOH-positive. By this cri-
terion, 18q LOH-positive cancers were detected in 36
(43 %) of 83 informative cases among 98 primary gastric
cancers (Table 2).
Similarly to the DCC methylation status, we investi-
gated associations between 18q LOH status and various
clinicopathological and genetic features. Among inform-
ative cases, the frequency of gastric cancer with distant
metastases was higher in 18q LOH-positive gastric can-
cers compared with 18q LOH-negative cancers (25 vs.
9 %, P = 0.041; Table 2). The LOH ratios calculated for
the other seven loci were also significantly higher for
18q LOH-positive than for 18q LOH-negative tumors
(0.44 vs. 0.10, P < .0001; Table 2). According to these re-
sults, when a tumor showed a LOH ratio higher than 0,
the tumor was categorized as CIN-positive. Furthermore,
CIN-positive gastric cancers that were also 18q LOH-
positive were significantly more abundant than those
that were 18q LOH-negative (74 vs. 38 %, P = 0.0017;
Table 2). Previous studies have demonstrated that 18q
loss is commonly observed in colorectal cancers, and its
frequency is correlated with CIN phenotype but inversely
correlated with MSI phenotype [29, 30]. As our study and
another study demonstrated, this phenomenon was also
reproduced for gastric cancers [18].
Expression and methylation status of DCC in gastric
cancer cell lines
To assess associations between DCC expression status
and epigenetic alterations in the DCC gene, we examined
messenger RNA (mRNA) levels by reverse transcription
quantitative polymerase chain reaction (RT-qPCR) using aprimer set previously described [31] and examined associ-
ations between DCC expression and CpG methylation
status in the DCC promoter region in 10 gastric cancer
cell lines (MKN7, N87, MKN74, MKN45, NUGC-2,
NUGC-3, NUGC-4, GCIY, OGUM-1, and MKN1) and
one normal lung fibroblast cell line (NHLF). All cell lines,
except for MKN74, GCIY, OGUM-1, MKN1, and NHLF
cells, showed decreased expression of DCC gene tran-
scripts, and their promoters were methylated (Fig. 1e).
On the other hand, although three cell lines, N87,
OGUM-1, and MKN1 showed decreased expression of
DCC gene transcripts, DCC promoters in those cells
were not methylated by COBRA. Among the 10 gastric
cancer cell lines, only the GCIY cell line expressed DCC
transcripts at the same level as NHLF cells, but its
promoter was methylated. When we categorized a cell line
showing aΔCT of more than 15.0 as DCC expression-
negative and a cell line with aΔCT of 15.0 or less as DCC
expression-positive, only the GCIY cell line could be cate-
gorized as DCC expression-positive among the seven
gastric cancer cell lines with DCC methylation; this find-
ing was statistically non-significant.Reduction of DCC expression requires both genetic and
epigenetic alterations
Next, we investigated the association between DCC pro-
tein expression and genetic and epigenetic alterations in
the DCC gene in 86 gastric cancer specimens. Represen-
tative examples of immunohistochemistry (IHC) staining
results are shown in Fig. 2a–c. We categorized tumors
into the following three groups based upon the IHC
results analyzed as a categorical variable: complete loss
of DCC expression (8 cases, 9 %; Fig. 2a), focal loss of
DCC expression (38 cases, 44 %; Fig. 2b), and positive
DCC protein expression (40 cases, 47 %; Fig. 2c). Among
86 gastric cancers, 46 cases (53 %) displayed reduced
DCC expression. A previous study reported that reduced
DCC expression was observed in a total of 38 % of
gastric cancers, and stage T1–T2 tumors maintained a
positive DCC expression while it was abolished in T3
tumors [32]. This finding was also reproducible in this
study (Additional file 2: Figure S2).
Table 2 Association between epigenetic/genetic alterations of the DCC gene and clinicopathological features in gastric cancers
DCC Methylation Status—% (No.) 18q LOH Status—% (No.) DCC Alteration Status—% (No.)
Unmethylation Methylation P Not
informative
Negative Positive P Not
informative
Negative Positive Positive P
Total Methylation alone LOH alone Both
(n = 54) (n = 44) (n = 15) (n = 47) (n = 36) (n = 15) (n = 25) (n = 58) (n = 22) (n = 19) (n = 17)
Age Mean age (SD) 63.6 (12.5) 67.0 (10.7) 0.48a 68.9 (11.4) 64.8 (11.4) 63.9 (12.4) 0.76a 68.9 (11.4) 63.5 (12.9) 64.8 (11.3) 66.3 (9.5) 60.7 (12.7) 67.4 (11.4) 0.98a
Gender Female 39 (21) 30 (13) 0.33b 40 (6) 38 (18) 28 (10) 0.32b 40 (6) 44 (11) 29 (17) 32 (7) 32 (6) 24 (4) 0.19b
Male 61 (23) 70 (31) 60 (9) 62 (29) 72 (26) 60 (9) 56 (14) 71 (41) 68 (15) 68 (13) 76 (13)
Histology Diff 41 (22) 59 (26) 0.071b 47 (7) 55 (26) 42 (15) 0.22b 47 (7) 52 (13) 48 (28) 59 (13) 32 (6) 53 (9) 076b
Undiff 59 (32) 41 (18) 53 (8) 45 (21) 58 (21) 53 (8) 48 (12) 52 (30) 41 (9) 68 (13) 47 (8)
Stage IA/IB 20 (11) 16 (7) 0.83b 13 (2) 19 (9) 19 (7) 0.15b 13 (2) 24 (6) 17 (10) 14 (3) 21 (4) 18 (3) 0.70b
IIA/IIB 26 (14) 34 (15) 27 (4) 30 (14) 31 (11) 27 (4) 24 (6) 33 (19) 36 (8) 32 (6) 29 (5)
IIIA/IIIB/IIC 39 (21) 36 (16) 53 (8) 43 (20) 25 (9) 53 (8) 40 (10) 33 (19) 45 (10) 26 (5) 24 (4)
IV 15 (8) 14 (6) 7 (1) 9 (4) 25 (9) 7 (1) 12 (3) 17 (10) 5 (1) 21 (4) 29 (5)
T T1a/1b 15 (8) 14 (6) 0.24b 7 (1) 17 (8) 14 (5) 0.94b 7 (1) 16 (4) 16 (9) 18 (4) 21 (4) 6 (1) 0.54b
T2 13 (7) 16 (7) 13 (2) 15 (7) 14 (5) 13 (2) 16 (4) 14 (8) 14 (3) 11 (2) 18 (3)
T3 20 (11) 36 (16) 33 (5) 28 (13) 25 (9) 33 (5) 16 (4) 31 (18) 41 (9) 16 (3) 35 (6)
T4a/b 52 (28) 34 (15) 47 (7) 40 (19) 47 (17) 47 (7) 52 (13) 40 (23) 27 (6) 53 (10) 41 (7)
N N0 30 (16) 23 (10) 0.66b 20 (3) 28 (13) 28 (10) 0.29b 20 (3) 32 (8) 26 (15) 23 (5) 32 (6) 24 (4) 0.19b
N1 37 (20) 32 (14) 47 (7) 38 (18) 25 (9) 47 (7) 44 (11) 28 (16) 32 (7) 26 (5) 24 (4)
N2 20 (11) 30 (13) 20 (3) 26 (12) 25 (9) 20 (3) 20 (5) 28 (16) 32 (7) 21 (4) 29 (5)
N3 13 (7) 16 (7) 13 (2) 9 (4) 22 (8) 13 (2) 4 (1) 19 (11) 14 (3) 21 (4) 24 (4)
Distant metastasis Negative 85 (46) 86 (38) 0.87b 93 (14) 91 (43) 75 (27) 0.041b 93 (14) 88 (22) 83 (48) 95 (21) 79 (15) 71 (12) 0.55b
Positive 15 (8) 14 (6) 7 (1) 9 (4) 25 (9) 7 (1) 12 (3) 17 (10) 5 (1) 21 (4) 29 (5)
MSI status MSI 6 (3) 23 (10) 0.013b 33 (5) 9 (4) 11 (4) 0.69b 33 (5) 4 (1) 12 (7) 14 (3) 0 (0) 24 (4) 0.25b
Non-MSI 94 (51) 77 (34) 67 (10) 91 (43) 89 (32) 67 (10) 96 (24) 88 (51) 86 (19) 100 (19) 76 (13)
LOH ratio Mean ratio (SD) 0.23 (0.30) 0.26 (0.31) 0.55a 0.22 (0.29) 0.10 (0.15) 0.44 (0.36) <0.0001a 0.22 (0.29) 0.05 (0.10) 0.33 (0.33) 0.16 (0.18) 0.44 (0.34) 0.44 (0.39) <0.0001a
CIN* Positive 46 (25) 57 (25) 0.39b 47 (7) 38 (18) 74 (25) 0.0017b 47 (7) 24 (6) 66 (37) 55 (12) 76 (13) 71 (12) 0.0005b
Negative 54 (27) 43 (19) 53 (8) 62 (29) 26 (9) 53 (8) 76 (19) 34 (19) 45 (10) 24 (4) 29 (5)
KRAS/BRAF/PIK3CA Mutant 6 (3) 11 (5) 0.30b 27 (4) 6 (3) 3 (1) 0.45b 27 (4) 4 (1) 5 (3) 9 (2) 5 (1) 0 (0) 0.82b
Wild 94 (51) 89 (38) 73 (11) 94 (44) 97 (35) 73 (11) 96 (24) 95 (55) 91 (20) 95 (18) 100 (17)
H.pyroli Positive 72 (39) 70 (31) 0.85b 80 (12) 66 (31) 75(27) 0.37b 80 (12) 60 (15) 74 (43) 73 (16) 79 (15) 71 (12) 0.20b
Negative 28 (15) 30 (13) 20 (3) 34(16) 25 (9) 20 (3) 40 (10) 26 (15) 27 (6) 21 (4) 29 (5)
*Two cases are not informative of CIN status
aP value were calculated between unmethylation and methylation, 18qLOH negative and positive, and DCC alteration negative and positive(total) by Wilcoxon/Kruskal–Wallis test











































Fig. 2 DCC promoter methylation and immunohistochemistry analyses. Immunohistochemistry analysis for DCC (a–c). Nuclei of tumor cells are
completely negatively (a), focally negatively (b), and positively (c) stained. (d) Association between epigenetic/genetic alteration and DCC expression
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epigenetic alterations and DCC expression status. Seven
of 8 cases with complete loss, 33 of 38 cases with focal
loss, and 34 of 40 cases with positive DCC expression
were informative for both DCC promoter methylation
and 18q LOH. We found that among the cancers with
complete loss of DCC expression, 5/7 cancers (71 %)
demonstrated both DCC promoter methylation and 18q
LOH. In contrast, 8/33 cancers (24 %) showed focal loss
of DCC expression and both methylation and LOH,
5/33 cancers (15 %) showed LOH alone, and 12/33
cancers (36 %) displayed methylation alone. Among
the cancers that were positive for DCC expression,
only 2/34 cancers (6 %) demonstrated both methyla-
tion and LOH, 13/34 (38 %) cancers LOH alone, and
8/34 cancers (24 %) methylation alone (cancers show-
ing both DCC methylation and 18q LOH vs. the
others, P = 0.0048, Pearson’s chi-square test; Fig. 2d).
Our data suggest that a reduction in DCC expressionmay require dense methylation in the promoter CpGs
and LOH of the 18q locus, according to the two-hit
theory [33].
Association between clinicopathological features and
genetic/epigenetic alterations of DCC in gastric cancer
Since both epigenetic and genetic alterations are critical
to DCC suppression, we investigated the relationship
between epigenetic and genetic alterations in the DCC
gene with various clinicopathological features. Of 98
gastric cancers, 15 cancers were categorized as non-
informative, 25 cancers were categorized as negative for
DCC alterations, and 58 cancers were categorized as
positive for DCC alterations. Among clinicopathological
features, LOH ratio and CIN phenotype distribution
differed significantly between cancers negative and posi-
tive for DCC alterations (Table 2).
Among the 58 cancers with DCC alterations, 17 tu-
mors showed alterations in both DCC methylation and
Toda et al. Clinical Epigenetics  (2015) 7:73 Page 8 of 1818q LOH, 19 had 18q LOH alone, and 22 cancers exhib-
ited DCC methylation alone. The LOH ratio calculated
for the other seven loci was significantly highest in
gastric cancers with both DCC methylation and 18q
LOH (mean LOH ratio, 0.44; SD ±0.39) and in cancers
with 18q LOH alone (mean LOH ratio, 0.44; SD ±0.34),
intermediate in cancers with DCC methylation alone
(mean LOH ratio, 0.16; SD ±0.18), and lowest in can-
cers negative for DCC alterations (mean LOH ratio,
0.05; SD ±0.10; P < 0.0001, Wilcoxon/Kruskal–Wallis
test). When we categorized gastric cancers with LOH
ratios higher than 0 as CIN-positive, 12/17 gastric cancers
(71 %) with both DCC methylation and 18q LOH, 13/17
gastric cancers (76 %) with 18q LOH alone, 12/22 gastric
cancers (55 %) with DCC methylation alone, and 6/25
cancers (24 %) negative for DCC alterations were catego-
rized as CIN-positive (P = 0.0025, Pearson’s chi-square
test). Our data suggest that DCC alterations caused by
both epigenetic and genetic alterations were signifi-
cantly associated with gastric cancers exhibiting the
CIN phenotype.Methylation profiles of UNC5C in
gastric cancer specimens
UNC5C methylation status was examined in a cohort of
98 gastric cancers and 105 normal gastric mucosa speci-
mens. Location of the UNC5C gene and a panel of rep-
resentative COBRA results are depicted in Fig. 3a–b.
We analyzed these results using UNC5C methylation
levels as continuous variables. We found that 39/98
gastric cancers (40 %) and 16/105 normal gastric mucosa
specimens (15 %) displayed more than 1 % methylation
in the UNC5C promoter. Of the samples that showed
more than 1 % methylation in the UNC5C promoter,
mean methylation levels of UNC5C were significantly
higher in gastric cancers compared with their corre-
sponding normal gastric mucosa specimens (17.4 %
(95 % CI, 12.4–22.4 %] in gastric cancers; 6.3 % (95 %
CI, 3.1–9.5 %] in normal gastric mucosa specimens;
P < 0.0001, Wilcoxon/Kruskal–Wallis test; Fig. 3c–d).
Using these results, we optimized a cutoff value of
UNC5C methylation of 5 % (>5 % methylation as
positive and <5 % methylation as negative). Using this
cutoff value, 31/98 gastric cancers (32 %) and 5/105
normal gastric mucosa specimens (5 %) were diag-
nosed as UNC5C-methylated. Next, we examined as-
sociations between UNC5C promoter methylation
status and the clinicopathological and genetic features
of gastric cancers. UNC5C methylation showed a signifi-
cant association with MSI status. MSI-positive gastric
cancers were significantly more frequent in gastric cancers
with UNC5C methylation compared with those without
UNC5C methylation (26 vs. 7 %, P = 0.013; Table 3). Therewere no significant associations between UNC5C methyla-
tion status and any of the other variables.
Expression and methylation status of UNC5C in gastric
cancer cell lines
Before examining UNC5C expression and methylation
status in the UNC5C promoter region in the gastric
cancer cell lines, we assessed the expression status of
five splicing variants of UCNC5C mRNA (UNC5C-001,
002, 003, 004, and 201) by RT-PCR (Additional file 3:
Figure S3). When analyzing five splicing variants of
UCNC5C messenger RNA in 10 gastric cancer cell lines
(MKN7, N87, MKN74, MKN45, NUGC-2, NUGC-3,
NUGC-4, GCIY, OGUM-1, and MKN1) and one normal
lung fibroblast cell line (NHLF), we found that only two
cell lines, GCIY and NHLF, expressed all five splicing
variants of UCNC5C messenger RNA. In nine gastric
cancer cell lines, there was no expression of any of the
five splicing variants of UCNC5C mRNA (Additional
file 4: Figure S4). Thus, further examination of mRNA
expression levels by RT-qPCR was performed using
the UNC5C 001–004 primer set. Among the 10 gas-
tric cancer cell lines, only the GCIY cell line exhibited
increased UNC5C mRNA expression levels (lowerΔCT,
Fig. 3e). When we categorized UNC5C mRNA expression
status by RT-PCR results (Additional files 4 and 5: Figures
S4 and S5), 93 % (13/14) of UNC5C methylated cell lines
lacked UNC5C mRNA expression, whereas 33 % (1/3) of
UNC5C unmethylated cell lines lacked UNC5C mRNA
expression (P = 0.01, Pearson’s chi-square test). Thus,
UNC5C gene transcript expression was significantly asso-
ciated with promoter methylation level. Additionally, we
tried to perform IHC staining for UNC5C protein expres-
sion. Unfortunately, we were unable to analyze UNC5C
protein expression due to lack of appropriate antibodies.
LOH of the 4q locus associated with CIN phenotype in
gastric cancer
The frequencies of 4q21–23 LOH at each microsatellite
marker for UNC5C were 29 % (11/38 informative cases)
at D4S2380, 23 % (10/44) at D4S470, and 28 % (12/43)
at D4S1559 (location of each maker is shown in Fig. 3a).
Tumors showing LOH at all three, two, and only one of
the three microsatellite markers amounted to 3 (3.8 %),
5 (6.3 %), and 15 (20 %) of 79 informative cases among
98 primary gastric cancers, respectively. We defined 4q
LOH-positive tumors as those showing LOH on at least
one of the three microsatellite markers. Tumors showing
4q LOH were found in 23 (29 %) of 79 informative cases
among 98 primary gastric cancers (Table 3). We found
that differentiated adenocarcinomas were significantly
more frequently observed in cancers with 4q LOH (65 %
in 4q LOH-positive cancers vs. 39 % in 4q LOH-negative
ones, P = 0.036).
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Fig. 3 UNC5C promoter methylation and 4q LOH analyses. (a) Schematic representation of the location of the three LOH probes and UNC5C
gene promoter regions in chromosome 4. The red line denotes the UNC5C gene. Gray and black squares represent the untranslated and the
coding exon 1 regions, respectively; arrows on the squares indicate transcriptional starting sites; vertical lines indicate CpG sites; white diamonds
represent the restriction sites for HhaI; thick horizontal lines depict the location of COBRA products; arrows on the thick horizontal lines denote
COBRA primers. (b) Representative results of COBRA of UNC5C. Arrows indicate methylated alleles; M denotes methylation; U denotes unmethylation; Mc
denotes the methylated control; SM denotes the size marker. (c) Results of UNC5C methylation as a continuous variable. In the box plot diagrams, the
horizontal line within each box represents the median, the limits of each box represent the interquartile ranges, and the whiskers denote the maximum and
minimum values. Each green bar represents the mean. NM denotes normal mucosa. T denotes tumor. (d) The frequency of methylation-positivity for
cancer and normal tissues according to different thresholds. (e) UNC5C mRNA expression levels and methylation status in 10 gastric cancer cell lines
and a human lung fibroblast cell line. UNC5C mRNA expression is observed (lower ΔCT) in GCIY and NHLH cell lines. DW denotes distilled water
Toda et al. Clinical Epigenetics  (2015) 7:73 Page 10 of 18Similar to 18q LOH, we found a strong correlation
between 4q LOH and CIN phenotype. The LOH ratio
calculated for the remaining seven loci was significantly
higher in gastric cancers with 4q LOH compared with
those without 4q LOH (0.40 vs. 0.15, P < 0.0001; Table 3).
According to these results, when a tumor showed a
LOH ratio higher than 0, the tumor was categorized as
CIN-positive, and CIN-positive gastric cancers were
significantly more frequent in the presence of 4q LOH
(83 % in 4q LOH-positive tumors vs. 37 % in 4q LOH-
negative ones, P = 0.0003; Table 3). While there were no
significant associations among any of the other vari-
ables, all KRAS/PIK3CA mutations were found in 4q
LOH-negative gastric cancers with a non-significant
difference (P = 0.08).
Association between clinicopathological features and
genetic/epigenetic alterations of UNC5C in gastric cancer
Next, we investigated the relationship between UNC5C
alterations and clinicopathological features. Of 98 gastric
cancers, 19 cancers were categorized as non-informative,
39 cancers were categorized as negative for UNC5C
alterations, and 40 cancers as positive for UNC5C alter-
ations. Cancers with UNC5C alterations were more fre-
quently observed in advanced stages (37 % (14/38) for
stages I and II vs. 63 % (26/41) for stages III and IV,
P = 0.02, Pearson’s chi-square test) and in advanced
categories for lymph node metastasis (25 % (5/20) for
N0 vs. 59 % (35/59) for N1–N3, P = 0.008, Pearson’s
chi-square test).
Among the 40 cancers with UNC5C alterations, 10
cancers showed alterations both in terms of UNC5C
methylation and 4q LOH, 13 cancers showed 4q LOH
alone, and 17 cancers showed UNC5C methylation
alone. The LOH ratio calculated for the remaining
seven loci was significantly higher in cancers with
both UNC5C methylation and 4q LOH (mean LOH
ratio, 0.45; SD ±0.36) and in those with 4q LOH alone
(0.37 ± 0.25), intermediate in cancers with UNC5C
methylation alone (0.24 ± 0.29), and lowest in cancers
negative for UNC5C alterations (0.11 ± 0.22, P = 0.0002,
Wilcoxon/Kruskal–Wallis test). When we categorized the
cancers that showed LOH ratios higher than 0 as CIN-positive, 8/10 gastric cancers (80 %) with both
UNC5C methylation and 4q LOH, 11/13 gastric can-
cers (85 %) with 4q LOH alone, 9/17 gastric cancers
(53 %) with UNC5C methylation alone, and 11/39
cancers (30 %) negative for UNC5C alterations were
categorized as CIN-positive (P = 0.001, Pearson’s chi-
square test). Similar to the DCC alterations in gastric
cancer, our data highlight that UNC5C alterations
caused by both epigenetic and genetic events were signifi-
cantly associated with CIN-positive gastric cancers.
Cumulative loss of netrin-1 receptors accrues with gastric
cancer progression
Because UNC5C and DCC both serve as dependence re-
ceptors for netrin-1, we investigated whether defects in
these receptors accumulate in a systematic or stochastic
manner during the progression of gastric carcinoma.
Therefore, we looked for associations between UNC5C
and/or DCC defects and TNM stage in the 98 gastric
cancers that were informative for both UNC5C and
DCC genetic/epigenetic results (Fig. 4 and Additional
file 6: Table S1). Concurrent alterations in the DCC and
UNC5C genes were observed significantly more com-
monly in advanced stages (64 % (21/ 33) for stages III
and IV) than in earlier-stage cancers (24 % (8/33) for
stages I and II, P = 0.001, Pearson’s chi-square test;
Fig. 4a). By stratifying gastric cancers based on individ-
ual defects in either UNC5C or DCC and their relation-
ship with tumor stage, UNC5C alterations were found in
18 % (2/11 informative cases), 48 % (12/25 informative
cases), 63 % (19/30 informative cases), and 64 % (7/11
informative cases) of stages I, II, III, and IV cancers,
respectively, showing that UNC5C alterations gradually
developed according to the progression of the TNM
stage (Table 3). On the other hand, DCC alterations
were constantly observed with a high frequency in all
TNM stages; hence, DCC alterations were found in 63 %
(10/16 informative cases), 76 % (19/25 informative
cases), 66 % (19/29 informative cases), and 77 % (10/13
informative cases) of stages I, II, III, and IV cancers,
respectively (Table 2). Therefore, this differential feature
found for each gene taken into consideration indicates
that cumulative alterations of netrin-1 receptors are
Table 3 Association between epigenetic/genetic alterations of the UNC5C gene and clinicopathological features in gastric cancers
UNC5 Methylation Status—% (No.) 4q LOH Status—% (No.) UNC5C Alteration Status—% (No.)
Unmethylation Methylation P Not
informative
Negative Positive P Not
informative
Negative Positive Positive P
Total Methylation alone LOH alone Both
(n = 67) (n = 31) (n = 19) (n = 56) (n = 23) (n = 19) (n = 39) (n = 40) (n = 17) (N = 13) (N = 10)
Age Mean age (SD) 64.3 (12.6) 66.7 (9.7) 0.49a 60.2 (12.6) 65.4 (12.3) 68.3 (8.2) 0.42a 60.2 (12.6) 64.8 (13.3) 67.8 (8.9) 67.0 (10.0) 67.2 (8.3) 69.8 (8.2) 0.36a
Gender Female 36 (24) 32 (10) 0.73b 47 (9) 36 (20) 22 (5) 0.23b 47 (9) 33 (13) 30 (12) 41 (7) 38 (5) 0 (0) 0.75b
Male 64 (43) 68 (21) 53 (10) 64 (36) 78 (18) 53 (10) 67 (26) 70 (28) 59 (10) 62 (8) 100 (10)
Histology Diff 48 (32) 52 (16) 0.72b 58 (11) 39 (22) 65 (15) 0.036b 58 (11) 41 (16) 52 (21) 35 (6) 54 (7) 80 (8) 0.31b
Undiff 520(35) 48 (15) 42 (8) 61 (34) 35 (8) 42 (8) 59 (23) 48 (19) 65 (11) 46 (6) 20 (2)
Stage IA/IB 22 (15) 10 (3) 0.17b 26 (5) 21 (12) 4 (1) 0.29b 26 (5) 28 (11) 5 (2) 6 (1) 8 (1) 0 (0) 0.03b
IIA/IIB 33 (22) 23 (7) 21 (4) 29 (16) 39 (9) 21 (4) 33 (13) 30 (12) 18 (3) 38 (5) 40 (4)
IIIA/IIIB/IIIC 31 (21) 52 (16) 37 (7) 38 (21) 39 (9) 37 (7) 28 (11) 48 (19) 59 (10) 31 (4) 50 (5)
IV 13 (9) 16 (5) 16 (3) 13 (7) 17 (4) 16 (3) 10 (4) 18 (7) 18 (3) 23 (3) 10 (1)
T T1a/1b 18 (12) 6 (2) 0.20b 21 (4) 16 (9) 4 (1) 0.49b 21 (4) 21 (8) 5 (2) 6 (1) 8 (1) 0 (0) 0.15b
T2 16 (11) 10 (3) 11 (2) 14 (8) 17 (4) 11 (2) 18 (7) 13 (5) 6 (1) 15 (2) 20 (2)
T3 22 (15) 39 (12) 26 (5) 25(14) 35 (8) 26 (5) 23 (9) 33 (13) 29 (5) 23 (3) 50 (5)
T4a/4b 43 (29) 45 (14) 42 (8) 45 (25) 43 (10) 42 (8) 38 (15) 50 (20) 59 (10) 54 (7) 30 (3)
N N0 31 (21) 16 (5) 0.06b 32 (6) 32 (18) 9 (2) 0.19b 32 (6) 38 (15) 13 (5) 18 (3) 15 (2) 0 (0) 0.03b
N1 39 (26) 26 (8) 42 (8) 30 (17) 39 (9) 42 (8) 33 (13) 33 (13) 24 (4) 38 (5) 40 (4)
N2 19 (13) 35 (11) 11 (2) 25 (14) 38 (8) 11 (2) 21 (8) 35 (14) 35 (6) 31 (4) 40 (4)
N3 10 (7) 23 (7) 16 (3) 13 (7) 17 (4) 16 (3) 8 (3) 20 (8) 24 (4) 15 (2) 20 (2)
Distant metastasis Negative 87 (58) 84 (26) 0.72b 84 (16) 88 (49) 83 (19) 0.57b 84 (16) 90 (35) 39 94 (16 ) 100 (13) 100 (10) 0.35b
Positive 13 (9) 16 (5) 16 (3) 13 (7) 17 (4) 16 (3) 10 (4) 0 6 (1) 0 (0) 0 (0)
MSI MSI 7 (5) 26 (8) 0.013b 21 (4) 14 (8) 4 (1) 0.21b 21 (4) 10 (4) 5 24 (4) 0 (0) 10 (1) 0.75b
Non-MSI 93 (62) 74 (23) 79 (15) 86 (48) 96 (22) 79 (15) 90 (35) 35 76 (13) 100 (13) 90 (9)
LOH Ratio Mean ratio (SD) 0.21 (0.28) 0.31 (0.35) 0.19a 0.32 (0.36) 0.15 (0.25) 0.40 (0.29) <0.0001a 0.32 (0.36) 0.11 (0.22) 0.33 (0.30) 0.24 (0.29) 0.37 (0.25) 0.45 (0.36) 0.0001a
CIN* Positive 49 (32) 58 (18) 0.42b 58 (11) 37 (20) 83 (19) 0.0003b 58 (11) 30 (11) 28 53 (9 ) 85 (11) 80 (8) 0.004b
Negative 51 (33) 42 (13) 42 (8) 63 (34) 17 (4) 42 (8) 70 (26) 12 47 (8) 15 (2) 20 (2)
KRAS/BRAF/PIK3CA Mutant 6 (4) 13 (4) 0.24b 5 (1) 13 (7) 0 (0) 0.08b 5 (1) 8 (3) 4 24 (4) 0 (0) 0 (0) 0.72b
Wild 94 (63) 87 (27) 95 (18) 88 (49) 100 (23) 95 (18) 92 (36) 36 76 (13) 100 (13) 100 (10)
H.pyroli Positive 72 (48) 71 (22) 0.95b 68 (13) 70 (39) 78 (18) 0.44b 68 (13) 67 (26) 9 24 (4) 15 (2) 30 (3) 0.28b
Negative 28 (19) 29 (9) 32 (6) 30 (17) 22 (5) 32 (6) 33 (13) 31 76 (13) 85 (11) 70 (7)
*Two cases are not informative of CIN status
aP value were calculated between unmethylation and methylation, 4qLOH negative and positive, and UNC5C alteration negative and positive(total) by Wilcoxon/Kruskal–Wallis test




















































































































































































Fig. 4 (See legend on next page.)
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Fig. 4 Association between alteration patterns in netrin-1 receptors and clinicopathological features in gastric cancers. Correlation between alterations in
netrin-1 receptors and TNM stage (a), depth of invasion (b), and degree of regional lymph node metastasis (c); association between alteration patterns in
netrin-1 receptors and LOH ratio (d), presence of distant metastasis (e), MSI status (f), CIN phenotype (g), and KRAS/BRAF/PIC3CA mutation status (h). *The
P value in panel A was calculated between Stage I/II vs. III/IV by Pearson’s chi-square test. ** The P value in panel c was calculated between N0 vs. N1–N3
by Pearson’s chi-square test. In Panel (d), the horizontal line within each box represents the median, the limits of each box represent the interquartile
ranges, and the whiskers are the maximum and minimum values in the box plot diagrams. Asterisks and the numbers denote the mean value of the
LOH ratio. Pairwise comparisons for each of the subgroups in panel (d) were performed by a non-parametric multiple comparison method using the
Steel–Dwass test. ***Two cases could not be evaluated for CIN phenotype
Toda et al. Clinical Epigenetics  (2015) 7:73 Page 13 of 18associated with gastric cancer progression. With respect
to the factors that determine TNM classification, a cu-
mulative loss of netrin-1 receptors was more strongly as-
sociated with the degree of regional lymph node
metastasis (N factor, Fig. 4c) compared with the tumor
status of T factors (Fig. 4b). Interestingly, gastric cancers
with defects in either UNC5C or DCC did not show dis-
tant metastasis (Fig. 4e), suggesting that the cumulative
alterations of netrin-1 receptors was a late event in gas-
tric cancer progression, significantly associated with
CIN-positive gastric cancers through increasing the
LOH ratio (Fig. 4d, g) rather than MSI and mutational
status (Fig. 4f ). On the other hand, there were no signifi-
cant associations between cumulative loss of netrin-1 re-
ceptors and any other clinicopathological variables
(Additional file 7: Figure S6).
Discussion
This study investigated the molecular events responsible
for the abrogation of the netrin pathway in gastric can-
cer and the role played by the two dependence recep-
tors, DCC and UNC5C. We analyzed 98 gastric cancers
and 105 adjacent normal mucosa specimens. We found
that the frequency of gastric cancers with concurrent al-
terations in the DCC and UNC5C genes increased in a
stage-dependent manner. Upon stratifying gastric can-
cers based on defects in either DCC or UNC5C and on
their relationship with tumor stage, we found that DCC
alterations were consistently observed in all TNM stages
with a high frequency: 10 of 16 (63 %) of stage I, 19 of
25 (76 %) of stage II, 19 of 29 (66 %) of stage III, and 10
of 13 (77 %) of stage IV cancers (Table 2). Meanwhile,
UNC5C alterations gradually increased according to the
progression of the TNM stage and were found in 2/11
(18 %) of stage I, 12 of 25 (48 %) of stage II, 19 of 30
(63 %) of stage III, and 7 of 11 (64 %) of stage IV cancers
(Table 3). Both DCC and UNC5C were inactivated in
97 % of CIN-positive gastric cancers and in 55 % of
CIN-negative gastric cancers, and these alterations
occurred through genetic and epigenetic processes.
These data provide novel evidence that the timing of
molecular alterations in DCC and UNC5C is not ran-
dom, because DCC inactivation occurs through alltumor stages, whereas UNC5C inactivation accrues grad-
ually during multistep gastric carcinogenesis.
Cells expressing netrin-1 receptors can send a survival
signal when they are engaged by netrin-1. On the other
hand, these receptors will send a death signal when they
are disengaged [34]. Thus, a loss of netrin-1 receptors
on tumor cells represents a loss of dependence receptors
that are capable of mediating apoptosis, resulting in
enhanced tumor cell survival [35].
The netrin-1 receptor, DCC, was discovered as a puta-
tive tumor suppressor gene in colorectal cancer [21].
DCC is located on chromosome 18q, which is the most
common deleted chromosomal region in colorectal
cancer as well as gastric cancer [13, 36–38, 12, 14]. The
tumor-suppressor role for DCC has been questioned in
studies that failed to show a clear malignant phenotype
in DCC knockout mouse models [20]. However, recent
studies have also challenged this hypothesis and have
suggested a role for DCC in suppressing tumor growth
and metastasis [24, 25]. Recent indications that DCC
serves as a dependence receptor for netrin-1 have
renewed the hypothesis that DCC functions as a pro-
apoptotic growth suppressor when not bound to its
ligand [34, 39, 12, 10]. In the gastrointestinal tract,
netrin-1 has an important role in the maintenance and
renewal of the intestinal epithelium by regulating cell
survival or cell death through its interaction with its
receptors, DCC and UNC5C [24, 34, 39]. In line with
previous studies [11, 8], in this study, we demonstrated
that methylation-induced silencing of DCC as well as
allelic loss of 18q was critical to loss of DCC expression.
Thus, reduction of DCC expression may require dense
CpG promoter methylation and LOH of the 18q locus
according to the two-hit theory as a common behavior
of tumor suppressor genes [33].
The other netrin-1 receptors, UNC5A, UNC5B, and
UNC5C, were also discovered as putative tumor sup-
pressor genes in various tumors [26, 27]. Among them, a
twofold downregulation of UNC5C expression compared
with corresponding normal tissue was observed in ap-
proximately 70 % of gastric cancer cases [26]. Therefore,
we focused on UNC5C that may play a more critical role
for gastric carcinogenesis. Additionally, it was suggested
Toda et al. Clinical Epigenetics  (2015) 7:73 Page 14 of 18that the loss of UNC5C was caused by allelic losses of
chromosome 4q, and mutations were rarely observed
[26]. Allelic losses at the 4q locus have been reported
previously in several human cancers, with frequencies
ranging from 23–39 % [26, 32, 18]. In accordance with
previous studies, in the present study, the frequencies of
allelic loss at 4q21–23 LOH were 29 % (11/38 inform-
ative cases) on D4S2380, 23 % (10/44) on D4S470, and
28 % (12/43) on D4S1559. Finally, gastric cancers dem-
onstrating allelic loss at 4q were found in 29 % (23/79)
of the informative cases. Another mechanism underlying
the loss of UNC5C in human cancers is represented by
epigenetic alterations. Indeed, we previously reported
that UNC5C was silenced by dense methylation of its pro-
moter CpG islands in colorectal cancer [28]. As is the case
in colorectal cancer, our results demonstrated that 11/12
gastric cancer cell lines (Fig. 3e and Additional files 3
and 4: Figures S3–S4) lacking UNC5C expression
showed dense methylation in the UNC5C promoter.
In clinical specimens, 31/98 gastric cancers (32 %)
and 5/105 normal gastric mucosa specimens (5 %) ex-
hibited UNC5C methylation. Therefore, we performed
UNC5C IHC on the clinical specimens to examine
the two-hit theory in which aberrant promoter methyla-
tion and allelic losses were the key factors determining
lack of DCC. However, we were unable to perform
UNC5C IHC on the clinical specimens because of the lack
of an appropriate antibody for tissue staining.
Because both DCC and UNC5C share the same netrin
ligand and are colocalized in the gut [24, 23, 26, 40], we
hypothesized that solitary inactivation of either DCC or
UNC5C may not be sufficient to promote tumor devel-
opment in the stomach. In this study, we found that
97 % of gastric cancers with CIN and 55 % of those
without CIN showed simultaneous alterations in both
DCC and UNC5C, supporting our hypothesis that inacti-
vation of both receptors may be required in the develop-
ment of gastric cancer. Our finding that dysregulation of
DCC predominantly occurs in the early phase of gastric
cancer whereas UNC5C alterations occur later suggests
that inactivation of these receptors is not a random
process but occurs in a statistically predictable, sequen-
tial manner.
H. pylori in the human gastric mucosa is a well-known
inducer of chronic inflammation and gastric cancers and
is associated with a high incidence of aberrant DNA
methylation [7, 41, 30, 29]. So, we detected H. pylori in-
fection by recovering the cagA repeat sequence from
gastric cancer specimens as well as normal gastric mu-
cosa samples. Of 98 cancers, 70 cancers were positive
for the cagA sequence. However, there was no associ-
ation between the presence of the cagA sequence in
cancer tissue and clinicopathological and molecular
features, specifically not DCC nor UNC5C methylationincidence. Conversely, with respect to normal counter-
part gastric mucosa, a total of 102 normal gastric mu-
cosa samples were available for analyzing the presence
of the cagA sequence in this study. Of 102 gastric mu-
cosa samples, the cagA sequence was successfully recov-
ered in 79 (74 %). Interestingly, when we defined DCC
and UNC5C methylation at 1 % or more as a continuous
variable (i.e., >1.0 % methylation as methylation-positive
(methylated) and <1.0 % methylation as methylation-
negative (unmethylated)), only UNC5C methylation was
significantly associated with the presence of the cagA
sequence in normal gastric mucosa (data not shown),
suggesting that inflammatory processes associated with
H. pylori infection causes aberrant methylation in
UNC5C promoter CpGs but not in the DCC promoter.
Thus, our results suggested that H. pylori infection does
not induce aberrant methylation randomly but in target
loci by a particular signal cascade. To address questions
underlying H. pylori infection and epigenetic changes,
further investigations are warranted.Conclusions
We provide previously unrecognized and novel evidence
that most gastric cancers, particularly those with CIN,
possess alterations in both DCC and UNC5C receptors.
Such alterations are apparent in the early stages and
continue to escalate in both receptor types with disease
progression, emphasizing the importance of this growth
regulatory pathway in gastric carcinogenesis.Methods
Primary gastric specimens
We collected tissue specimens of primary gastric cancer
and matched normal gastric mucosa from 105 patients
who had undergone surgery at the Okayama University
Hospital (Okayama, Japan). Of 105 gastric cancer
patients, seven did not have sufficient tumor tissue for
analysis. Thus, in this study, a total of 98 gastric cancer
specimens and 105 matched normal gastric mucosa
tissues were analyzed. All normal gastric mucosa speci-
mens were obtained from sites adjacent to the tumor
but at least 5 cm away from the tumor site. All patients
provided written informed consent, and the study was
approved by the ethics committee of the Okayama
University Hospital. All patients also gave informed
consent for usage of their data for future analyses. The
histological diagnosis was established according to the
World Health Organization International Histological
Classification of tumors, with subclassification into two
histological categories: differentiated type (well and mod-
erately differentiated tubular adenocarcinoma) and undif-
ferentiated type (poorly differentiated adenocarcinoma
and mucinous adenocarcinoma). The pathological stage
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Against Cancer TNM classification (Seventh edition).Cell lines
A total of 12 human gastric cancer cell lines (MKN7,
N87, MKN74, MKN45, NUGC-2, NUGC-3, NUGC-4,
GCIY, OGUM-1, MKN1, MKN28, and KATO III), three
human colorectal cancer cell lines (SW48, SW480, and
SW837), one human colon fibroblast cell line (CCD18Co),
and one human lung fibroblast cell line (NHLF) were
purchased from American Type Culture Collections
(Manassas, VA, USA), Japanese Collection of Research
Bioresources Cell Bank (Ibaragi, Osaka, Japan), Health
Science Research Resources Bank (Chiyoda-ku, Tokyo,
Japan), RIKEN (Wako, Saitama, Japan), or Cambrex Bio
Science Walkersville, Inc. (East Rutherford, NJ, USA). All
cell lines were cultured in appropriate culture medium
supplemented with 10 % fetal bovine serum, penicillin
(100 IU/mL), and streptomycin (100 μg/mL) at 37 °C in a
humidified incubator with 5 % CO2.
DNA and RNA extraction
Genomic DNA from the cell lines was extracted using
QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA).
All gastric cancers and normal gastric mucosa samples
were fresh-frozen tissue specimens, from which DNA
was extracted using standard procedures that included
proteinase-K digestion and phenol–chloroform extrac-
tion. Total RNA from six cultured cell lines (MKN28,
KATO III, SW48, SW480, SW837, and CCD18Co) was
obtained using the TRIzol reagent (Invitrogen Life
Technologies Inc., Carlsbad, CA, USA). Total RNA from
10 gastric cancer cell lines (MKN7, N87, MKN74,
MKN45, NUGC-2, NUGC-3, NUGC-4, GCIY, OGUM-1,
and MKN1) and a normal lung fibroblast cell line, NHLF,
was isolated using the RNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions.
Reverse transcription polymerase chain reaction
The first-strand complementary DNA synthesis was per-
formed using the Moloney murine leukemia virus re-
verse transcriptase (Invitrogen Life Technologies Inc.)
and miScript II RT Kit (Qiagen) with a total of 1.0 μg
RNA. RT-PCR was performed using specific primer pairs
for UNC5C (including primers for the detection of
splicing variants), DCC, and beta-actin (Additional
file 8: Table S2). The PCR products were electropho-
resed on a 3.5 % agarose gel. By using the UNC5C
001–004-, DCC-, and beta-actin-specific primer pairs,
expression of UNC5C and DCC mRNA was also
determined by RT-qPCR using the SsoAdvanced
Universal SYBR Green Supermix on the LightCycler
480 (Roche Diagnostics). The expression level of eachtarget gene was analyzed based on the ΔCT method,
and beta-actin was used as an endogenous control to
normalize the amount of total RNA in each sample.Bisulfite modification and combined bisulfite
restriction analysis
Bisulfite modification of genomic DNA from cell lines
and clinical specimens was performed as described pre-
viously. The methylation status of the DCC and UNC5C
promoters in gastric tissues and cell lines was analyzed
by combined bisulfite restriction analysis (COBRA,
Additional file 8: Table S2). COBRA was carried out
in a 24.0-μL PCR reaction containing 12.0 μL of
HotStarTaq Master Mix (Qiagen) and 0.4 μM of each
primer. PCR products were digested with a restriction
enzyme HhaI (New England Biolabs Inc., Ipswich,
MA, USA) at 37 °C overnight. PCR products were
electrophoresed on a 3.0 % agarose gel. The percent-
age of methylated HhaI sites were calculated by deter-
mining the ratio between the HhaI-cleaved PCR
product and the total amount of PCR product loaded.LOH analyses and definition of CIN phenotype
A set of three polymorphic microsatellite markers per
gene was used to determine LOH at chromosomes 18q21
for DCC and 4q21–23 for UNC5C (Additional file 8: Table
S2). PCR amplifications were performed on genomic
DNA templates from both tumor and normal mucosa
tissue using fluorescently labeled primers. PCR products
were electrophoresed on an ABI 310R Genetic Analyzer
and analyzed by GeneMapper fragment analysis software
(Applied Biosystems, Foster City, CA, USA). When com-
paring the signal intensities of the individual markers in
the tumor DNA with that of the corresponding normal
DNA, a reduction by at least 40 % of the signal intensity
was considered indicative of LOH.
In addition, to examine the association between
netrin-1 receptor disorders and CIN phenotype, we ana-
lyzed additional seven sets of polymorphic microsatellite
sequences that are tightly linked to known tumor
suppressor genes and DNA mismatch repair genes, in-
cluding the MYCL locus on 1p34 (MYCL), the hMSH2
locus on 2p16 (D2S123), the APC locus on 5q21
(D5S346, D5S107), the UNC5D locus on 8p12 (D8S87),
and the p53 locus on 17p13 (D17S250, TP53) [31]. Of
98 gastric cancer patients, 96 patients displayed at least
one marker informative of LOH status. Hence, since two
patients turned out non-informative for LOH at all
seven microsatellite sequences, further analyses were
performed only on the 96 informative cases. CIN pheno-
type classification was performed by calculating the
LOH ratio of the informative markers of the seven poly-
morphic microsatellite sequences, independently from
Toda et al. Clinical Epigenetics  (2015) 7:73 Page 16 of 18the UNC5C and DCC loci. When a tumor showed a
LOH ratio higher than 0, the tumor was categorized as
CIN-positive.
MSI analysis and definition of MSI phenotype
MSI status was analyzed for all 98 gastric cancer patients
using three mononucleotide repeat markers (BAT26,
NR21, and NR27) as described previously [33]. When at
least one or more mononucleotide repeat markers dis-
played microsatellite instability, tumors were defined to
have an MSI phenotype, and tumors without MSI in the
three mononucleotide repeat markers were defined to
have a non-MSI phenotype.
KRAS, BRAF, and PIK3CA mutation analyses
KRAS and BRAF mutation status was analyzed in all 98
patients as described previously [35]. In addition,
PIK3CA exon 9 and 20 mutation status was also ana-
lyzed by direct sequencing. PCR and sequencing were
performed using PIK3CA exon 9- and 20-specific primer
pairs (Additional file 8: Table S2). PCR products were
electrophoresed on an ABI 310R Genetic Analyzer.
Detection of H. pylori
To determine H. pylori infection status, we recovered
the Glu-Pro-Ile-Tyr-Ara (EPIYA) repeat sequence in the
cagA protein, which binds to the Src homology 2
domain-containing protein tyrosine phosphatase, SHP-2,
on gastric epithelial cells. The cagA was recovered by
PCR amplification performed on genomic DNA templates
from tumor tissues. We modified the primer design to
develop PCR products shorter than the PCR products
described previously [42, 43]. PCR was carried out in a
24-μL PCR reaction containing 12 μL of HotStarTaq
Master Mix and 0.4 μM of each primer (Additional file 8:
Table S2). The PCR products were electrophoresed on a
3 % agarose gel.
Immunohistochemical analysis
A total of 89 gastric cancers from 98 patients were
available for IHC staining for DCC protein expression
analysis. Staining was carried out manually with
formalin-fixed paraffin-embedded tissues. Thin (5 μm)
sections of representative blocks were deparaffinized
and dehydrated using gradient solvents. Following
antigen retrieval in citrate buffer (pH 6.0), endogen-
ous peroxidase was blocked with 3 % H2O2. There-
after, slides were incubated overnight in the presence of a
purified mouse anti-human DCC monoclonal antibody
(clone G97–449, Pharmingen, San Diego, CA, USA;
dilution 1:100). A further incubation was carried out with
a secondary antibody and the avidin-biotin-peroxidase
complex (Vector Laboratories, Burlingame, CA, USA)
and then incubated with biotinyltyramide followed bystreptavidin-peroxidase. Diaminobenzidine was used
as a chromogen, and hematoxylin as a nuclear counter-
stain. Tissue sections with obvious nuclear staining were
considered positive. The only foci of neoplasia that were
scored as negative were those for which there was definite
evidence of unspecific positively staining admixed or
surrounding non-neoplastic cells such as normal colonic
mucosal cells, lymphocytes, or stromal cells.
Statistical analysis
Statistical analyses were performed using JMP software
(version 10.0; SAS Institute Inc., Cary, NC, USA). First,
DCC and UNC5C methylation levels were analyzed as
continuous variables, as were computed means, standard
errors of the means, and standard distributions. Next,
the methylation status of the DCC and UNC5C pro-
moter was analyzed as a categorical variable (positive,
methylation level >5 %; negative, methylation level < 5 %).
Differences in frequencies were evaluated by Pearson’s
chi-square test or the Wilcoxon/Kruskal–Wallis test.
Whenever the Kruskal–Wallis test indicated differences
among these subgroups, further pairwise comparisons for
each of the subgroup was performed by a non-parametric
multiple comparison method using the Steel–Dwass test.
All reported probability (P) values were two-sided,
and a P value of less than 0.05 was considered statis-
tically significant.
Additional files
Additional file 1: Figure S1. Examples of KRAS mutation and H. pylori
cagA analysis. (A) An example of KRAS codon 12 and 13 direct
sequencing analysis. This case showed both codon 12 and 13 mutations.
(B) To detect H. pylori infection, EPIYA repeat sequences in the cagA
protein were recovered from clinical materials. We found two types of
EPIYA repeat sequences, one was 159 bp and the other was 261 bp. SM
denotes the size marker; P and N denote positivity and negativity of
EPIYA repeat sequences, respectively.
Additional file 2: Figure S2. Association between DCC IHC status and
T factors.
Additional file 3: Figure S3. Splicing variants of UNC5C mRNA and
location of the primers which can distinguish expression status of the
splicing variants.
Additional file 4: Figure S4. Expression status of splicing variants of
UNC5C mRNA and association of UNC5C methylation for 10 gastric cancer
cell lines. Ten gastric cancer cell lines and NHLF cells were analyzed for
mRNA expression by RT-PCR of UNC5C splicing variants and beta-actin
genes. The lowest panel illustrates the methylation profile obtained from
COBRA.
Additional file 5: Figure S5. Association of UNC5C methylation and
loss of UNC5C mRNA expression in gastric cancer and colorectal cancer
cell lines. Two gastric cancer cell lines, three colorectal cancer cell lines, and
CCD18Co cells were analyzed for mRNA expression by RT-PCR of UNC5C and
beta-actin genes. The lowest panel illustrates the methylation profile obtained
from COBRA.
Additional file 6: Table S1. Association between alterations in netrin-1
receptors and clinicopathological features in gastric cancers.
Additional file 7: Figure S6. Association between alteration patterns in
netrin-1 receptors and clinicopathological features in gastric cancers.
Toda et al. Clinical Epigenetics  (2015) 7:73 Page 17 of 18Correlation between alterations in netrin-1 receptors and gender (A),
histology (B), H. pylori cagA expression status (C), and (D) age. In the box
plot diagrams, the horizontal line within each box represents the median,
the limits of each box are the interquartile ranges, and the whiskers denote
the maximum and minimum values. Asterisks plus numbers denote mean
age at surgery.
Additional file 8: Table S2. Primer sequences.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KT performed methylation and LOH analyses of both genes in the clinical
sample material and drafted the manuscript. TN assisted with the
interpretation of the data, designed the project, secured the funding, and
drafted the manuscript. YU and SK provided the patient samples and
clinicopathological data. TT performed IHC and collected pathological findings.
NK and YT assisted with methylation and LOH analyses of both genes in the
clinical sample material. HT and DSS assisted with the methylation and LOH
analyses in the cell lines and partially in the clinical sample material. TK and
TomF performed RT-PCR and RT-qPCR strategies for DCC and UNC5C in the cell
lines. FT and KY cultured all cell lines and examined the expression status of
UNC5C splicing variants. NN assisted with cell line work and IHC studies. AG
assisted with the interpretation of the data, co-designed the project, and revised
the manuscript. TosF provided patients’ samples and clinicopathological data,
assisted with the interpretation of the data, and revised the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Mr. Toru Nakai, Mrs. Tae Yamanishi, and
Mr. Akihiro Nyuya for technical assistance and Enago (www.enago.jp) for
English language editing. This work was supported by KAKENHI
(19390351 and 20590572).
Author details
1Department of Gastroenterological Surgery, Okayama University Graduate
School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City,
Okayama 700-8558, Japan. 2Department of Pathology, Okayama University
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Okayama City, Okayama 700-8558, Japan. 3Department of Oncology, Kailuan
General Hospital in Tangshan of Hebei Province, Tangshan, Hebei 063000,
China. 4Department of Gastroenterology and Hepatology, Kinki University
Faculty of Medicine, 337-2 Ohno-higashi, Osaka-sayama, Osaka 589-8511,
Japan. 5Center for Gastrointestinal Cancer Research, Center for Epigenetics,
Cancer Prevention and Cancer Genomics, Baylor Research Institute and
Charles A Sammons Cancer Center, Baylor University Medical Center, Dallas,
TX 75246, USA.
Received: 20 February 2015 Accepted: 17 June 2015
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107.
2. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular
and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643–55.
doi:10.1038/nrclinonc.2013.170.
3. Akhavan-Niaki H, Samadani AA. Molecular insight in gastric cancer
induction: an overview of cancer stemness genes. Cell Biochem Biophys.
2014;68:463–73. doi:10.1007/s12013-013-9749-7.
4. Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravallo G, Dammacco F. H.
pylori infection and gastric cancer: state of the art (review). Int J Oncol.
2013;42:5–18. doi:10.3892/ijo.2012.1701.
5. Figueiredo C, Garcia-Gonzalez MA, Machado JC. Molecular pathogenesis of
gastric cancer. Helicobacter. 2013;18:28–33. doi:10.1111/hel.12083.
6. Yoshida T, Kato J, Inoue I, Yoshimura N, Deguchi H, Mukoubayashi C, et al.
Cancer development based on chronic active gastritis and resulting gastric
atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori
antibody titer. Int J Cancer. 2014;134:1445–57. doi:10.1002/ijc.28470.7. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido
M, et al. Helicobacter pylori infection and the development of gastric
cancer. N Engl J Med. 2001;345:784–9. doi:10.1056/NEJMoa001999.
8. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, et al. Patterns of
genomic instability in gastric cancer: clinical implications and perspectives.
Ann Oncol. 2006;17:vii97–102. doi:10.1093/annonc/mdl960.
9. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island
methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A.
1999;96:8681–6.
10. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, et al. Aberrant
methylation in gastric cancer associated with the CpG island methylator
phenotype. Cancer Res. 1999;59:5438–42.
11. Keller G, Grimm V, Vogelsang H, Bischoff P, Mueller J, Siewert JR, et al.
Analysis for microsatellite instability and mutations of the DNA mismatch
repair gene hMLH1 in familial gastric cancer. Int J Cancer. 1996;68:571–6.
doi:10.1002/(SICI)1097-0215(19961127)68:5<571::AID-IJC3>3.0.CO;2-W.
12. Cancer Genome Atlas Research N. Comprehensive molecular
characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.
doi:10.1038/nature13480.
13. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, et al. A comprehensive
survey of genomic alterations in gastric cancer reveals systematic patterns
of molecular exclusivity and co-occurrence among distinct therapeutic
targets. Gut. 2012;61:673–84. doi:10.1136/gutjnl-2011-301839.
14. Tamura G, Ogasawara S, Nishizuka S, Sakata K, Maesawa C, Suzuki Y, et al.
Two distinct regions of deletion on the long arm of chromosome 5 in
differentiated adenocarcinomas of the stomach. Cancer Res. 1996;56:612–5.
15. Tamura G, Sakata K, Maesawa C, Suzuki Y, Terashima M, Satoh K, et al.
Microsatellite alterations in adenoma and differentiated adenocarcinoma of
the stomach. Cancer Res. 1995;55:1933–6.
16. Nishizuka S, Tamura G, Terashima M, Satodate R. Loss of heterozygosity
during the development and progression of differentiated adenocarcinoma
of the stomach. J Pathol. 1998;185:38–43. doi:10.1002/(Sici)1096-
9896(199805)185:1<38::Aid-Path58>3.0.Co;2-T.
17. Uchino S, Tsuda H, Noguchi M, Yokota J, Terada M, Saito T, et al. Frequent
loss of heterozygosity at the Dcc locus in gastric-cancer. Cancer Res.
1992;52:3099–102.
18. Hiyama T, Tanaka S, Yoshihara M, Sasao S, Kose K, Shima H, et al.
Chromosomal and microsatellite instability in sporadic gastric cancer.
J Gastroenterol Hepatol. 2004;19:756–60. doi:10.1111/j.1440-
1746.2004.03369.x.
19. Hahn SA, Schutte M, Hoque ATMS, Moskaluk CA, DaCosta LT, Rozenblum E,
et al. DPC4, a candidate tumor suppressor gene at human chromosome
18q21.1. Science. 1996;271:350–3. doi:10.1126/science.271.5247.350.
20. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al.
Progression of chronic atrophic gastritis associated with Helicobacter pylori
infection increases risk of gastric cancer. Int J Cancer. 2004;109:138–43.
doi:10.1002/ijc.11680.
21. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, et al.
Identification of a chromosome-18q gene that is altered in colorectal cancers.
Science. 1990;247:49–56. doi:10.1126/science.2294591.
22. Arakawa H. Netrin-1 and its receptors in tumorigenesis. Nat Rev Cancer.
2004;4:978–87. doi:10.1038/nrc1504.
23. Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, et al.
Deleted in colorectal cancer (DCC) encodes a netrin receptor. Cell.
1996;87:175–85.
24. Mazelin L, Bernet A, Bonod-Bidaud C, Pays L, Arnaud S, Gespach C, et al.
Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature.
2004;431:80–4. doi:10.1038/nature02788.
25. Rodrigues S, De Wever O, Bruyneel E, Rooney RJ, Gespach C. Opposing roles
of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor
growth and metastasis. Oncogene. 2007;26:5615–25. doi:10.1038/sj.onc.1210347.
26. Thiebault K, Mazelin L, Pays L, Llambi F, Joly MO, Scoazec JY, et al. The
netrin-1 receptors UNC5H are putative tumor suppressors controlling cell
death commitment. Proc Natl Acad Sci U S A. 2003;100:4173–8.
doi:10.1073/pnas.0738063100.
27. Bernet A, Mazelin L, Coissieux MM, Gadot N, Ackerman SL, Scoazec JY, et al.
Inactivation of the UNC5C Netrin-1 receptor is associated with tumor
progression in colorectal malignancies. Gastroenterology. 2007;133:1840–8.
doi:10.1053/j.gastro.2007.08.009.
28. Shin SK, Nagasaka T, Jung BH, Matsubara N, Kim WH, Carethers JM, et al.
Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in
Toda et al. Clinical Epigenetics  (2015) 7:73 Page 18 of 18human colon cancer. Gastroenterology. 2007;133:1849–57.
doi:10.1053/j.gastro.2007.08.074.
29. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, et al.
Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts
survival for colorectal cancer. J Clin Oncol. 2012;30:2256–64.
doi:10.1200/JCO.2011.38.6490.
30. Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM,
et al. Characterization of sporadic colon cancer by patterns of genomic
instability. Cancer Res. 2003;63:1608–14.
31. Srour M, Riviere JB, Pham JM, Dube MP, Girard S, Morin S, et al. Mutations in
DCC cause congenital mirror movements. Science. 2010;328:592.
doi:10.1126/science.1186463.
32. Graziano F, Cascinu S, Staccioli MP, Catalano V, Rossi MC, Baldelli AM, et al.
Potential role and chronology of abnormal expression of the deleted in
colon cancer (DCC) and the p53 proteins in the development of gastric
cancer. BMC cancer. 2001;1:9.
33. Goel A, Nagasaka T, Hamelin R, Boland CR. An optimized pentaplex PCR for
detecting DNA mismatch repair-deficient colorectal cancers. PloS one.
2010;5, e9393. doi:10.1371/journal.pone.0009393.
34. Mehlen P, Fearon ER. Role of the dependence receptor DCC in colorectal
cancer pathogenesis. J Clin Oncol. 2004;22:3420–8.
doi:10.1200/JCO.2004.02.019.
35. Castets M, Broutier L, Molin Y, Brevet M, Chazot G, Gadot N, et al. DCC
constrains tumor progression via its dependence receptor activity. Nature.
2012;482:534–7. doi:10.1038/nature10708.
36. Lei J, Zou TT, Shi YQ, Zhou X, Smolinski KN, Yin J, et al. Infrequent DPC4
gene mutation in esophageal cancer, gastric cancer and ulcerative colitis-
associated neoplasms. Oncogene. 1996;13:2459–62.
37. Leite M, Corso G, Sousa S, Milanezi F, Afonso LP, Henrique R, et al. MSI
phenotype and MMR alterations in familial and sporadic gastric cancer. Int J
Cancer. 2011;128:1606–13. doi:10.1002/ijc.25495.
38. Oue N, Mitani Y, Motoshita J, Matsumura S, Yoshida K, Kuniyasu H, et al.
Accumulation of DNA methylation is associated with tumor stage in gastric
cancer. Cancer. 2006;106:1250–9. doi:10.1002/cncr.21754.
39. Mehlen P, Llambi F. Role of netrin-1 and netrin-1 dependence receptors in
colorectal cancers. Br J Cancer. 2005;93:1–6. doi:10.1038/sj.bjc.6602656.
40. Leonardo ED, Hinck L, Masu M, Keino-Masu K, Ackerman SL, Tessier-Lavigne
M. Vertebrate homologues of C. elegans UNC-5 are candidate netrin receptors.
Nature. 1997;386:833–8. doi:10.1038/386833a0.
41. Moss SF, Blaser MJ. Mechanisms of disease: Inflammation and the origins of
cancer. Nat Clin Pract Oncol. 2005;2:90–7. doi:10.1038/ncponc0081. quiz 1 p
following 113.
42. Yamazaki S, Kato S, Matsukura N, Ohtani M, Ito Y, Suto H, et al. Identification
of Helicobacter pylori and the cagA genotype in gastric biopsies using
highly sensitive real-time PCR as a new diagnostic tool. FEMS Immunol Med
Microbiol. 2005;44:261–8. doi:10.1016/j.femsim.2004.12.011.
43. Argent RH, Zhang Y, Atherton JC. Simple method for determination of the
number of Helicobacter pylori CagA variable-region EPIYA tyrosine
phosphorylation motifs by PCR. J Clin Microbiol. 2005;43:791–5.
doi:10.1128/JCM.43.2.791-795.2005.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
